BlossomHill Therapeutics IPO: offering terms from its S-1
BlossomHill Therapeutics priced its IPO at $16 a share on 7 Aug 2026 and raised $150 million. Its shares trade on Nasdaq as BLSM.
Headlines
- Net loss, 2025
- $61M
- IPO price
- $16
- $150M raised
BlossomHill Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- BLSM
- IPO price
- $16
- Shares offered
- 9,375,000
- Raised
- $150M
- Registered
- $153M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital and H.C. Wainwright & Co.
- First filed
- 17 Jul 2026
BlossomHill Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$64M | -$61M |
| First quarter of 2026 | - | -$22M | -$21M |
BlossomHill Therapeutics share structure and company facts
- Employees
- 63
- Headquarters
- San Diego, California
BlossomHill Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 7 Aug 2026
- First close
- $16.00
- 0% on the IPO price
- Latest close
- $16.39
- +2% on the IPO price
BlossomHill Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from BlossomHill Therapeutics' newest prospectus (424B4 filed 7 Aug 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.